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Abstract 27 
 28 
MicroRNAs (miR) are epigenetic regulators of gene expression at the posttranscriptional 29 
level. They are involved in intercellular communication and crosstalk between different 30 
organs. As key regulators of homeostasis, their dysregulation underlies several disease 31 
conditions, including kidney disease. Moreover, their remarkable stability in plasma and 32 
urine makes them attractive biomarkers.  33 
Beyond biomarker studies, clinical microRNA research in the nephrology field has focused 34 
the last decennia on the discovery of specific microRNA signatures and the identification of 35 
novel targets for therapy and/or prevention. Heterogeneity of conducted research is, 36 
however, striking, and there is a current need for standardization and confirmation of new 37 
findings in large prospective trials.  38 
After discussing briefly the general concepts of microRNA, this review provides an overview 39 
of the available clinical evidence in both the pathophysiology and biomarker field for the 40 
role of microRNA in acute kidney injury and kidney transplantation.  41 
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Introduction 43 
 44 
MicroRNAs (miRs), an evolutionary conserved class of non-coding RNAs, are negative 45 
regulators of post-transcriptional gene expression (1). Sequence-specific binding to the 46 
target mRNA results in translational inhibition or mRNA degradation. microRNA 47 
dysregulation is involved in the development and progression of numerous diseases, 48 
including cancer, cardiovascular and kidney disease (2, 3). microRNA synthesis takes place 49 
through a canonical pathway involving four key enzymes or, alternatively, via the mirtron 50 
pathway (Figure 1). Genomic events or inhibition of regulatory enzymes all can lead to 51 
microRNA dysregulation in disease (5, 6). 52 
microRNAs execute their repressive function intracellularly, but they are also released into 53 
the extracellular compartment where they can act as hormones and/or biomarkers (Figure 54 
1). Apart from being released passively as a result of cell death or injury, microRNAs are 55 
actively secreted in different types of extracellular vesicles, including exosomes, 56 
microvesicles and apoptotic bodies. Circulating microRNAs form complexes with RNA 57 
binding proteins including Argonaute (AGO) 2 proteins and lipoproteins (HDL and LDL), 58 
which protects them from RNAse-dependent degradation (9). Interestingly, microRNAs are 59 
important intercellular communicators (for overview, see (7)+REF) in a paracrine or even 60 
endocrine way (for example in muscle-kidney crosstalk (8)). Following uptake, specific 61 
microRNA can exert their silencing function in the recipient cells. In vivo modulation (merely 62 
inhibition) of microRNA expression as a therapeutic strategy is widely explored and in 63 
chronic kidney disease (CKD), several microRNA-targeting drugs entered clinical testing 64 
based on convincing pre-clinical evidence (4, 11). In autosomal dominant polycystic kidney 65 
disease, insight in the pathogenetic role of miR-17 (12, 13) recently lead to the start of a 66 
phase I trial of an anti-miR-17 compound (known as RGLS4326). Likewise, miR-21 inhibition 67 
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in Alport syndrome shows promising results, both in an animal model and in in vitro studies 68 
of patients with Alport syndrome (13, 14). A phase I clinical trial with an anti-miR-21 69 
compound (RG-012) is ongoing in patients with Alport syndrome, thereby evaluating its 70 
safety and treatment efficacy (NCT03373786). In contrast with CKD, trials targeting 71 
microRNA in the field of acute kidney injury (AKI) or kidney transplantation have not entered 72 
the clinical phase yet.  73 
This review provides an overview of the available clinical evidence in both the pathogenic 74 
role and the diagnostic potential of microRNA in acute kidney injury and kidney 75 
transplantation. For a comprehensive review on the role of miRNA in CKD, we refer the 76 
reader to Lv et al (15). Table 1 and Table 2 show the current evidence for AKI and transplant-77 
related disorders, respectively. Several caveats apply when interpreting the study results. 78 
Firstly, the considerable heterogeneity in the applied techniques (qRT-PCR, microarrays, 79 
Next Generation Sequencing) (16) and patient groups studied, makes inter-group 80 
comparisons and indepent validation difficult. Secondly, several of these studies investigated 81 
microRNA target prediction and mRNA interactions through biostatistical modelling. 82 
Experimental validation however, remains important. Thirdly, natural inter-individual 83 
variation in microRNA expression levels is not well defined, neither across the life course, 84 
between cell types nor defined in response to variation in psychosocial factors or nutrition. 85 
These are established factors that affect kidney biology (17, 18). Technological 86 
developments, principally the use of single cell sequencing technologies, could add in-depth-87 
analysis in this area and enable a more comprehensive picture of both differing clinical 88 
epigenotypes and inter-individual variation in epigenotypes unrelated to any 89 
pathophysiology.  90 
 91 
microRNA in the pathophysiology of acute kidney injury and transplant-related disorders 92 
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Acute kidney injury 93 
From the limited experiments that were performed to date in human settings, microRNAs 94 
appear to act via different mechanisms. Some microRNAs repress pathways that play a 95 
protective role in renal physiology while a pro-inflammatory effect by inhibition of anti-96 
inflammatory pathways or mitochondrial function have also been described.   97 
A number of microRNAs appear to play a role in acute kidney injury (AKI), where the release 98 
of multiple interleukins precedes structural kidney damage (Figure 2). These include miR-101 99 
(interleukin 2, nuclear factor kappa B (NFkB) pathway) (19), miR-494 (activating transcription 100 
factor 3 in NFkB pathway) (20), miR-16 (BCL-2) (21) and miR-107 (tumor necrosis factor 101 
(TNF)) (22). Interestingly, urinary miR-494 levels, as opposed to serum levels, were found to 102 
increase early in critically ill AKI patients compared to their counterparts without AKI and 103 
healthy controls. In turn, miR-494 inhibits the expression of the kidney protective gene ATF3, 104 
resulting in more aggravated kidney injury (20). C/EBP-β (C/ enhancer binding protein-β) 105 
upregulated miR-16, which in turn blocked one of the anti-apoptotic genes, BCL-2 after 106 
ischemia/reperfusion-induced injury (21). In septic AKI patients, increased miR-107 induced 107 
TNF-α secretion by targeting DUSP7 (dual specificity protein phosphatase 7) in endothelial 108 
cells, which may directly cause tubular injury (22). In vitro inhibition of this microRNA 109 
resulted in attenuated TNF secretion and prevented subsequent tubular cell injury (22). In a 110 
study by Ge et al. (23), 37 microRNAs were differentially expressed in the serum of sepsis-111 
induced AKI versus sepsis non-AKI patients. Function and pathway analysis revealed that 8 of 112 
them were associated with 13 genes involved in mitochondrial oxidative stress and 113 
dysfunction response including peroxisome proliferator-activated receptor gamma 114 
coactivator 1-alpha (PGC-1α), sirtuin 1 (SIRT1), mammalian target of rapamycin (mTOR), 115 
oxidative stress responsive 1 (OXSR1) and NADPH oxidase 5 (NOX5) (23). Congruent with 116 
these observations, up-regulation of renal tubular miR-709 after cisplatin-induced AKI 117 
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hampers mitochondrial function and induces cell apoptosis by depressing mitochondrial 118 
transcriptional factor A expression (24). 119 
 120 
Kidney transplantation  121 
Ischemia/reperfusion injury and delayed graft function  122 
microRNAs are involved in the regulation of processes as angiogenesis and apoptosis 123 
through transforming growth factor beta (TGF-β), endothelin, vascular endothelial growth 124 
factor (VEGF) and platelet derived growth factor (PDGF) signalling (25). Up-regulation of 125 
miR-182-5p, miR-21-3p and miR146a have been reported in this context (26, 27). The 126 
overexpression of miR-146a probably represents a compensatory mechanism, since in vitro 127 
experiments identified the role of miR-146a as a negative regulator of inflammation in 128 
tubular cells by down-regulation of the NFkB /C-X-C motive chemokine ligand 8 (CXCL-8) 129 
pathway (27). In multivariate logistic regression analysis, the expression of miR-217 and miR-130 
125b (both involved in cellular stress and damage responses by influencing cyclin dependent 131 
kinase inhibitor 2 (CKDN2) loci transcript expression) in pre-implantation biopsies together 132 
with donor age and type were independently associated with delayed graft function. 133 
Delayed graft function could be predicted in 84% of cases, with 92.4% specificity and 64.3% 134 
sensitivity (28). More recently (McGuinness D, Shiels P et. al, personal communication), 135 
delayed graft function has been identified as a manifestation of allostatic overload at a 136 
transcriptional level. A composite indicator of accumulated biological stress over the life 137 
course is defined as allostatic load, which predisposes to morbidity in case of chronic or 138 
repeated stress exposure. Organs undergoing delayed graft function exhibited a greater 139 
magnitude of change in transcriptional amplitude and elevated expression of non-coding 140 
RNAs and pseudogenes, consistent with increased allostatic load than in those showing 141 
immediate graft function. Notably, this study incorporated a validation biopsy set and 142 
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individual validation of targets transcriptionally and post-transcriptionally. Additionally, it 143 
undertook a cross-comparison with publically available data sets for kidney pathologies, 144 
used to identify significant transcriptional commonality for over 20 delayed graft function 145 
transcripts, thus providing a clear molecular signature for the burden of ‘wear and tear’ 146 
within the kidney and age-related physiological capability and resilience. The expression of 147 
the CDKN2 locus transcripts in this cohort related to the delayed graft function outcome and 148 
perfusion status at the transcript level. These results indicate that CDKN2A/p16INK4, ARF/p14 149 
and CDKN2B  reflected the allostatic load (and biological age) of these organs pre-perfusion. 150 
Regulation of these loci by miR-125b is a notable feature. 151 
 152 
T-cell mediated rejection  153 
Global miR expression profiling of grafts with T-cell mediated rejection showed that miR-154 
142-5p, miR-155 and miR-223, could each predict T-cell mediated rejection with high 155 
sensitivity and specificity (Area under the curve (AUC) 0.96-0.99) (29). Their correlation with 156 
intra-graft CD3 and CD20 mRNA levels suggests that these miRs originate from immune cells 157 
infiltrated in the graft (29). Other groups have shown similar patterns for miR-142-5p (30), 158 
miR-155 (25, 30, 31), miR-223 (30-32). In addition, miR-10b (anti-apoptotic targeting BCL211 159 
(31)) and miR-30a-3p appeared to be down-regulated in rejecting graft tissue, while 160 
correlating with renal tubule specific mRNAs (Na+-K+-2Cl- cotransporter (NKCC-2) (29). In a 161 
small set of biopsies, eight miRs turned up to be upregulated and 12 miRs downregulated in 162 
T-cell mediated rejection (34), with some of them targeting pathways highly relevant in 163 
leukocyte function (for example hsa-miR-611 targeting glycosyltransferase like domain 164 
containing 1 (GTDC1)).  165 
Vitalone et al. (35) identified 19 miRs that may target the differentially expressed mRNAs in 166 
T-cell mediated rejection. Validation of these miRs in an independent set of biopsies 167 
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revealed significant up-regulation of 3 miRs (Table 1) and down-regulation of 6 miRs in 168 
rejecting vs non-rejecting graft tissue. All up-regulated miRs were associated with tubulitis 169 
and interstitial inflammation, suggesting infiltrating lymphocytes as the origin of these miRs, 170 
whereas miR-204, miR-210 and miR-10b-3p negatively correlated with Banff scores. The 171 
TGF-β signalling pathway, and in particular forkhead box P3 (FOXP3) regulated transcription, 172 
is common to the regulatory action of all these miRs (35).  173 
Oghumu et al. (32) have identified a panel of 25 miRs significantly different expressed in 174 
grafts from recipients with acute rejection compared to acute pyelonephritis. Interestingly, 175 
some previously reported down-regulated miRs in T-cell mediated rejection grafts including 176 
miR-23-3p (25), miR-30a-5p (29), miR-30d-5p (29), miR-30c-5p (29, 31) and miR-99b-5p (25) 177 
were significantly up-regulated in acute pyelonephritis compared to rejection biopsies (32).  178 
 179 
Antibody-mediated rejection  180 
Up-regulation of miR-146-5p, miR-182, miR-21-3p, miR-1228 and let-7i, involved 181 
in  inflammation, chemokine and cytokine signaling, apoptosis and interleukin signaling,  has 182 
been observed in grafts with antibody-mediated rejection (25). Increased miR-142-5p 183 
expression levels were observed in peripheral blood mononuclear cells and grafts from 184 
recipients with chronic antibody-mediated rejection compared to normal allografts and 185 
peripheral blood mononuclear cells from stable kidney transplant recipients. miR-142-5p 186 
overexpression was associated with down-regulation of 41 genes related to a cell-mediated 187 
immune response (36). Of note, miR-146-5p as well as miR-142-5p were also significantly up-188 
regulated in grafts with T-cell mediated rejection (29, 30). 189 
To unravel the molecular mechanisms underlying chronic antibody-mediated rejection, 190 
Rascio et al. (37) performed a combined mRNA and miR expression analysis in peripheral 191 
blood mononuclear cells from kidney recipients with chronic antibody-mediated rejection 192 
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and normal allografts. Four miRs were found to be modulators of 6 mRNAs involved in the 193 
type I interferon (IFN) signalling network. miR validation in an independent set of peripheral 194 
blood mononuclear cells revealed a significant down-regulation of miR-148b-3p, miR-29b-3p 195 
and miR-769-5p. Validation of these findings has not been forthcoming. No overlapping miR 196 
signature could be identified with the data of Danger et al. (36), possibly related to 197 
methodological differences and definition of the controls. 198 
 199 
Interstitial fibrosis and tubular atrophy  200 
Fifteen miRs have been identified as being of interest in interstitial fibrosis and tubular 201 
atrophy (IF/TA), relating to regulation of lymphocyte proliferation, B, T and natural killer (NK) 202 
cell activation/differentiation. The expression of five of these miRs has been independently 203 
validated, with miR-142-3p (38, 39) and miR-32 being up-regulated and miR-204, miR-107 204 
and miR-211 (39) being down-regulated in grafts with IF/TA (40). The up-regulation of miR-205 
142-5p, miR-21 (41), miR-223 and down-regulation of miR-30b, miR-30c and miR-338-3p was 206 
found by Ben-Dov et al. (38) and confirmed in an independent but small set of IF/TA 207 
biopsies. Bioinformatic analysis has identified SMAD 7 (an inhibitor of TGFβ mediated 208 
fibrosis) as a possible target of miR-21.  209 
Of note, similar miR expression data for miR-142-3p (29, 30, 32, 35), miR-142-5p (29, 30), 210 
miR-223 (29-31), miR-204 (29, 32, 35), miR-30c (29, 31, 32) and miR-30b (29) was found in 211 
intragraft miR profiling studies in rejecting allografts, T cell-mediated rejection in particular.  212 
 213 
microRNA as biomarkers of kidney disease 214 
microRNAs are highly stable in both plasma and urine, making them attractive biomarkers 215 
(10).  216 
 217 
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Acute kidney injury 218 
AKI coincides with reduced expression levels of most, but not all, circulating miRs (42). In the 219 
plasma of AKI patients, miR-16 and miR-320 were found to be down-regulated, while miR-220 
210 was up-regulated (43). This upregulation appeared to be a strong independent 221 
prognostic factor for 28-day survival of critically ill patients with AKI (43). Likewise, urinary 222 
levels of miR-21 and miR-155 could successfully distinguish patients with and without AKI 223 
(44). This is in keeping with other findings that urinary miR-21 appeared to be more 224 
associated with AKI prognosis and other adverse clinical outcomes than plasma miR-21 225 
levels (45, 46). In contrast to the Du study (46), serum miR-21 was down-regulated in 2 226 
studies that included patients who developed AKI after cardiac surgery. Serum miR-21 levels 227 
turned up to be predictive for the development of AKI when sampled prior to cardiac 228 
surgery (AUC 0.70) (48) and 6h after cardiac surgery (AUC 0.90) (49). In the latter study, also 229 
urinary miR-21 levels were predictive for AKI (49). Interestingly, ischemic preconditioning 230 
could increase endogenous miR-21 expression and further protect kidney function (50).  231 
Urinary miR-200c and miR-423 were up-regulated in AKI patients based on microRNA array 232 
analyses (45). In a small longitudinal study, a panel of 10 miRs could be used for AKI 233 
diagnosis in Intensive Care Unit (ICU) patients with nearly 100% sensitivity and specificity 234 
and 4 of them were associated with AKI severity (47). Another set of four miRs was 235 
associated with AKI development several days before serum creatinine in cardiac surgery 236 
patients (47). miR-192 was put forth to diagnose AKI when sampled 2h after cardiac surgery, 237 
however, with a rather poor sensitivity (66.7%) and specificity (62.9% ) (51). Likewise, 238 
urinary miR-30c-5p performed well also as a biomarker of AKI after cardiac surgery, and 239 
even better compared to protein-based markers such as neutrophil gelatinase-associated 240 
lipocalin (NGAL) and kidney injury molecule-1 (Kim-1) (52). In contrast-induced nephropathy, 241 
miR-30a, -c and –e appeared to be significantly higher in comparison with patients who 242 
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received contrast but without nephropathy, with a peak at 12h after the contrast 243 
administration (53). Although all 3 miRs correlated positively with serum creatinine, they 244 
only increased in 55.5% of the contrast-induced nephropathy patients while they remained 245 
stable in 44.5% of the patients. The positive predictive value of these 3 microRNAs varied 246 
between 91.3% and 94.9% while the negative predictive value varied between 61.3 and 247 
78.2% (53). Sun et al. (54) confirmed the increase of miR-30a and –e and, in addition, they 248 
found miR-188 to be increased in a similar population.  249 
 250 
Transplantation 251 
The value of microRNA as biomarkers of different graft-associated pathologies were 252 
investigated either by quantification of a set of miRs known to be dysregulated in the graft 253 
(27, 30, 39-41, 55-57) or involved in pathways of interest (58) or by performing a global miR 254 
profiling on blood cells (36, 59), serum or plasma (33, 60) and urine (57, 61). 255 
 256 
Ischemic-reperfusion injury 257 
A significant up-regulation of miR-146a was observed in urine samples of recipients 258 
transplanted with a deceased donor, compared to a living donor and was thus suggested as 259 
a diagnostic marker for ischemia/reperfusion injury injury (27).  260 
 261 
T-cell mediated rejection 262 
Both senescence associated miR-223 and miR-142-3p are up-regulated in the graft and 263 
peripheral blood mononuclear cells of patients with acute T-cell mediated rejection (30). 264 
Increased miR-223 levels, along with increased levels of miR-10a, were also observed in the 265 
serum of a small number transplant recipients during T-cell mediated rejection (55). The up-266 
regulation of serum miR-99a and miR-100 was also reported in kidney transplant recipients 267 
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with T-cell mediated rejection with serum miR-99a levels discriminating recipients with 268 
acute rejection from stable transplant recipients (AUC 0.75) and recipients with delayed 269 
graft function (AUC 0.81) (60). However, previous miR profiling studies reported decreased 270 
levels of miR-99a expression in T-cell mediated rejection kidney allografts (29, 32). Paired 271 
tissue and blood analysis should therefore be performed to determine the significance of 272 
these conflicting results. 273 
In multivariate logistic regression analysis, a panel of 5 miRs isolated from blood cells (miR-274 
15b, miR-16, miR103a, miR106a and miR-107) could accurately discriminate an acute 275 
vascular rejection (Banff II-III) from stable graft function (AUC 0.97). The difference between 276 
T-cell mediated vascular rejection and all other phenotypes (Borderline, Banff I and 277 
antibody-mediated rejection) was less distinct (AUC 0.82) (59).  278 
Urinary levels of miR-10a showed to be significantly up-regulated, while miR-10b and miR-279 
210 were down-regulated in urine samples of recipients with acute T-cell mediated rejection 280 
compared to recipients with stable graft function. Furthermore, expression levels of urinary 281 
miR-210, involved in cellular aging, related to biopsy-proven rejection severity with levels 282 
normalizing after rejection treatment. However, receiver operating characteristic (ROC) 283 
analysis revealed a rather weak specificity of 52% and sensitivity of 74% (AUC 0.70) for the 284 
distinction between acute rejection and stable graft function (61). A decreased expression of 285 
miR-210-3p was confirmed in urine pellets from transplant recipients with T-cell mediated 286 
rejection (56). In this study, higher expression levels of urine miR-155-5p – also reported as 287 
highly expressed in the graft during acute T-cell mediated rejection (25, 29-31) – were more 288 
discriminative for the diagnosis of acute rejection (AUC 0.88) and in a few cases, increased 289 
levels or miR-155-5p were observed prior to the rejection episode (56).  290 
 291 
Antibody-mediated rejection 292 
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In peripheral blood mononuclear cells from recipients with chronic, but not acute, antibody-293 
mediated rejection, miR-142-5p was upregulated. In ROC analysis, the discriminative 294 
capacity for chronic antibody-mediated rejection versus stable controls was rather fair with 295 
an AUC of 0.74 (36). Although the authors suggest the specificity of this miR in chronic 296 
antibody-mediated rejection, other groups also reported increased levels of this 297 
hematopoietic miR in peripheral blood mononuclear cells and grafts of recipients with an 298 
acute T-cell mediated rejection (29, 30).  299 
 300 
Interstitial fibrosis and tubular atrophy  301 
Lower miR-211 and miR-204 expression levels and  an up-regulation of miR-142-3p were 302 
found in urine pellets of recipients with a biopsy proven IF/TA compared to recipients with a 303 
normal histology and graft function (40). miR levels in the urine appeared to be correlated 304 
with miR expression levels in the graft (40). These findings were confirmed in a cohort of 305 
recipients with established IF/TA (57). A significant down-regulation of miR-200b, miR-375, 306 
miR-193b and up-regulation of miR-423-5p and miR-345 has been observed in these two 307 
miR discovery datasets. A larger prospective validation study revealed a significant down-308 
regulation of miR-200b in urine pellets of recipients with established IF/TA one year after 309 
transplantation compared to recipients without IF/TA. No correlation was found between 310 
the expression of miR-200b and proteinuria (57). A significant down-regulation of miR-200b 311 
was also reported in plasma samples of recipients with IF/TA compared to stable kidney 312 
transplant recipients (58). Higher expression levels of miR-21 were measured in serum from 313 
recipients with a biopsy proven IF/TA thereby showing a gradually increase with IF/TA 314 
severity. ROC analysis for the diagnosis of severe IF/TA (grade III) revealed an AUC of 0.89. 315 
Furthermore, no correlations were found between miR-21 levels and the presence of other 316 
acute or chronic Banff lesions in this study, although study groups were small (41). 317 
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Discussion and conclusion 318 
 319 
Insight in the pathophysiological role of microRNA in chronic kidney disease is growing, and 320 
miR targeting therapies are being introduced in the clinic. In acute kidney disease and 321 
transplantation, on the contrary, the role of microRNAs in the pathophysiological processes 322 
are still in the exploratory phase and thus need several confirmation and validation steps 323 
before they can be seen as a therapeutic target. From the few papers that have been 324 
published to date in acute kidney injury, microRNAs is a strong regulator of the NFκB 325 
pathway. This pathway has long been considered as a major target in –inflammatory 326 
diseases because of its role in proinflammatory cytokine production, cell survival and 327 
leucocyte recruitment. Lately, it became, however, clear that the NFκB pathway also plays a 328 
role in the protection processes against inflammation thanks to its anti-apoptitic functions. 329 
This dual mechanism hampered the development of anti-NFκB pathway drugs. In the 330 
transplantation field, more insights in the pathophysiology of transplant related processes as 331 
well as diagnostic biomarkers for diagnosis are eagerly awaited. A biomarker is ‘a 332 
characteristic that is objectively measured and evaluated as an indicator of normal biological 333 
processes, pathogenic responses, or pharmacological responses to a therapeutic 334 
intervention’ (ref). As their remarkable stability in body fluids make them attractive 335 
biomarkers, several microRNAs are put forward as biomarkers for the diagnosis of kidney 336 
diseases and transplant related pathologies. Clinically useful biomarkers should have a high 337 
sensitivity and specificity, a high negative and positive predictive value and a diagnostic AUC 338 
nearing 1.0. Currently, these latter characteristics remain under the desired results, which 339 
hamper the clinical implementation of microRNAs as diagnostic or prognostic markers of 340 
disease. After transplantation, a combined panel of five miRs, however, was able to 341 
discriminate T-cell mediated vascular rejection form stable graft function with an AUC of 342 
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0.97 (ref). Most probably, combining the right microRNAs to a diagnostic panel will be the 343 
future.  Nowadays, most studies remain in the exploratory phase and there is an urgent 344 
need for larger clinical prospective trials to validate the results and thoroughly investigate 345 
their diagnostic and prospective potential. Next, a standardized method for sampling and 346 
analysis is highly recommended to improve between-group comparison in external 347 
validation set-ups.  348 
 349 
Search terms 350 
The following databases were used: Pubmed and Web of Science. No limits were applied on 351 
publication date and last data base search was performed on May 25th 2018. The following 352 
Mesh terms were used: ‘microRNA or microRNA or miR AND acute kidney injury’; microRNA 353 
or microRNA or miR AND renal function’; ‘microRNA or microRNA or miR AND acute renal 354 
impairment’ ‘MicroRNAs AND Kidney Transplantation’. Only papers on human research were 355 
withheld for this review. 356 
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Table 1: microRNAs in acute kidney injury 
 
 
microRNA AND PATHOPHYSIOLOGY 
 
Phenotype Study (author) Study population Sample miR Internal 
validation 
(independent 
cohort) 
Overlap with other studies 
Upregulation Downregulation 
AKI Lan YF et al. (2012)(1) Critical patients with AKI 
(n=16)  
Critical patients without AKI 
(n=10)  
Healthy controls (n=14) 
Serum and urine 
samples 
↑ urinary miR-494 
in AKI patients 
-  - - 
AKI Wang S et al.(2017)(2) Septic AKI (n=15) 
Non-septic AKI (n=15) 
Septic non-AKI (n=15) 
Healthy volunteers (n=15) 
 
Circulating 
endothelial cells 
↑ miR-107 in 
septic AKI patients 
-  - - 
AKI Chen et al (2016)(3) Critical patients with AKI 
(n=11)  
Critical patients without AKI 
(n=7)  
Healthy volunteers (n=4) 
Serum and urine 
samples 
↑ urinary let-7d, 
life-26-3p, miR-16, 
miR-451, miR-486-
5p, miR-518*, miR-
720 
↓ 21 miRs 
miR-16 was 
further 
validated in 
animal studies 
- - 
AKI Kang et al. (4) Children after cardiac 
surgery: 
Control group (n=249): 
- AKI (n=115) 
- Non-AKI (n=134) 
RIPC group (n=200) 
Plasma and 
urine 
↑ miR-21 after 
RIPC 
- - - 
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- AKI (n=38) 
- Non-AKI (n=162) 
AKI Guo et al. (5) AKI patients with cisplatin 
(n=21) 
Kidney biopsy ↑ miR-709 - - - 
AKI Liu et al. (6) AKI patients (n=4) peripheral blood 
mononuclear 
cells 
Overexpression of 
miR-101 led to 
reduced c-Rel and 
IL-2 expression 
   
AKI Ge et al. (7) Discovery cohort: 
Septic AKI (n=6) 
Septic non-AKI (n=6) 
Controls (n=3) 
 
Validation cohort: 
Septic AKI (n=35) 
Septic non-AKI (n=30) 
Serum  40 miRs were 
differentially 
expressed 
between AKI and 
non-AKI patients 
↑ miR-4270, 
miR-4321, miR-
3165 
↓ miR-142-5p, 
miR-22-3p, 
miR-191-5p, 
miR-23a-3p, 
miR-4456 
- - 
 
microRNA AS BIOMARKERS 
 
Phenotype Study (author) Study population Sample miR Internal 
validation 
(independent 
cohort) 
Overlap with other studies 
Upregulation Downregulation 
AKI Lorenzen (2011) (8) Discovery cohort: 
Critically ill patients with AKI 
(n=5) 
Healthy controls (n=5) 
 
Validation cohort: 
AKI (n=77) 
Healthy controls (n=30) 
AMI (n=18) 
Plasma  13 miRs were 
different between 
AKI patients and 
healthy controls 
↓miR-16 and 
miR-320 in AKI 
↑ miR-210 in 
AKI 
 
- - 
Ischemic or Saikumar (2012) (9) Critically ill patients with Urine   ↑ miR-21 in AKI - ↑ miR-21 (10, 11) - 
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septic AKI elevated Scr and elevated 
levels of urinary KIM-1 
(n=22) 
Healthy volunteers ‘n=25) 
↓ miR-155 in AKI 
 
 
 
Severe AKI Du (2013) (10) Stage 1 or 2 AKI defined by 
AKIN after cardiac surgery 
(n=80) 
Non-AKI group (n=40) 
Urine and 
plasma 
↑ miR-21 in AKI in 
both urine and 
plasma samples 
 
- ↑ miR-21 (9, 11) - 
AKI Ramachandran (2013) 
(11) 
Discovery cohort: 
ICU patients with AKI (n=6) 
Healthy volunteers (n=6) 
 
Validation cohort: 
Healthy volunteers (n=74) 
ICU patients without kidney 
disease (n=23) 
ICU patients with AKI (n=71) 
Kidney Tx patients with 
tubular injury (n=27) 
Urine  
 
378 microRNAs 
were selected for 
validation with 
qPCR in the 
validation cohort 
↑ miR-21, miR-
200c, miR-423 
in AKI patients 
↓ miR-4640 in 
AKI patients 
↑ miR-21 (9, 10) - 
AKI Aguado-Fraile (2015) 
(12) 
Discovery cohort: 
ICU patients (n=4) 
Healthy volunteers (n=10) 
 
Validation cohort:  
ICU patients (n=35) 
Cardiac surgery patients 
(n=41) 
Healthy volunteers (n=20) 
 
Serum 10 miRs were 
selected (more 
than 2-folds 
change) 
↓ miR-101-3p, 
miR-127-3p, 
miR-210-3p, 
miR126-3p, 
miR-26b-5p, 
miR-29a-3p, 
miR-146a-5p, 
miR-27a-3p, 
miR-93-3p, 
miR-10a-5p in 
AKI in ICU 
patients 
 
↓ miR-127-3p, 
miR-26b-5p, 
miR-146a-5p, 
miR-93-3p in 
patients after 
- - 
25 
 
 
 
Abbreviations: n: number; AKI: acute kidney injury; AMI: acute myocardial infarction; Scr: serum creatinine; KIM-1: kidney injury molecule-1 ; AKIN: acute kidney injury Network; ICU: intensive 
care unit; miR: microRNA, RIPC: remote ischemic preconditioning, qPCR: quantitative polymerase chain reaction. 
  
CS 
 
AKI Zou (2017) (13) AKI after cardiac surgery 
(n=27) 
Non-AKI after cardiac 
surgery (n=44) 
Urine  ↑ miR-30c-5p, 
miR-192-5p, miR-
378a-3p 
- ↑ miR-30c (14) 
↑ miR-192(15) 
- 
Contrast-
induced AKI 
Gutiérrez-Escolano 
(2015) (14) 
contrast-induced 
nephropathy patients 
(n=92) 
Non-contrast-induced 
nephropathy patients 
(n=92) 
Plasma  ↑ miR-30a, -c and 
-e 
- ↑ miR-30a (16) 
↑ miR-30c (13) 
↑ miR-30e (16) 
- 
Contrast-
induced AKI 
Sun et al. (2016) (16) Patients with AKI after 
elective coronary 
angiography or 
percutaneous coronary 
intervention (n=71) 
Plasma  
 
↑ miR-188, miR-
30a and -e 
- ↑ miR-30a (14) 
↑ miR-30e (14) 
- 
AKI Arvin et al. (2017)(17) Stage 2-3 AKI after cardiac 
surgery (n=18) 
Stage 0-1 AKI after cardiac 
surgery (n=97) 
Serum and urine ↓ urinary and 
serum miR-21 
- - ↓serum miR-21(18) 
AKI Gaede et al. (2016)(18) AKI after cardiac surgery 
(n=14) 
Non-AKI after cardiac 
surgery (n=14) 
Serum  ↓ serum miR-21 - - ↓serum miR-21(17) 
AKI Zhang et al. (2017) (15) AKI after cardiac surgery 
(n=35) 
Non-AKI after cardiac 
surgery (n=35) 
Plasma  ↑ miR-192 - ↑ miR-192(13)  
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Table 2: microRNA in kidney transplantation 
 
 
microRNA AND PATHOPHYSIOLOGY 
 
Phenotype Study (author) Study population Sample miR Internal 
validation 
Overlap with other studies 
Upregulation Downregulation 
ATN/delayed graft 
function 
Wilflingseder et al., 2013 
(19) 
ATN (n=14) 
normal PBX (n=10) 
Biopsy ↑ 7 miRs - ↑ miR-21-3p (20) 
↑ miR-182-5p 
(20) 
- 
ATN/delayed graft 
function 
Wilflingseder et al., 2014 
(20) 
ATN + T0BX (n=8) 
normal PBX + T0BX 
(n=10) 
Biopsy ↑ 29 miRs - ↑ miR-21-3p (19) 
↑ miR-182-5p 
(19) 
- 
ATN/delayed graft 
function 
Amrouche et al., 2016 
(21) 
ATN (n=19) 
Normal PBX (n=15) 
Biopsy ↑ miR-146a - - - 
ATN/delayed graft 
function 
McGuinness et al., 2016 
(22) 
Discovery cohort: 
T0BX good performing 
allografts within 2 years 
post-Tx (n=5) 
T0BX poor performing 
allografts within 2 years 
post-Tx (n=5)   
 
Validation cohort: 
T0BX delayed graft 
function (n=27) 
T0BX no delayed graft 
function (n= 67) 
 
Model validation 
cohort:  
T0BX delayed graft 
function (n=10)  
Biopsy 11 differentially 
expressed miRs 
(fold changes not 
reported) 
↓ miR-125b 
↓ miR-217 
- - 
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T0BX no delayed graft 
function (n=14)  
Acute T-cell mediated 
rejection  
(Banff I) 
Sui et al., 2008 (23) T-cell mediated 
rejection (n=3) 
resected tissue RCC 
(n=3) 
Biopsy ↑ 8 miRs 
↓ 12 miRs 
 
 
- ↑ miR-125a (24)  
↑ miR-602 (24)  
↑ miR-628 (24)  
↑ miR-658 (24)  
 
↓ miR-17-3p (24) 
↓ miR-330 (24) 
↓ miR-483 (24)  
↓ miR-611 (24)  
↓ miR-663 (24) 
Acute T-cell mediated 
rejection  
(Banff I) 
Anglicheau et al., 2009 
(25) 
Discovery cohort: 
T-cell mediated 
rejection (n=3) 
normal PBX (n=4) 
 
Validation cohort: 
T-cell mediated 
rejection (n=9) 
normal PBX (n=17) 
 
Biopsy ↑ 10 miRs 
↓ 43 miRs 
 
 
↑ miR-142-5p 
↑ miR-155 
↑ miR-223 
 
↓ miR-10b 
↓ miR-30a-3p 
↑ miR-142-3p 
(26-28)  
↑ miR-155 (19, 
24, 28) 
↑ miR-223 (24, 
27, 28)  
↑ miR-342-3p 
(26, 27) 
↑ miR-142-5p 
(28)  
↑ miR-21 (24)  
↑ miR-146a (24)  
↑ miR-650 (24)  
 
 
 
 
 
↓ miR-30c (24, 27) 
↓ miR-125a (19, 27) 
↓ miR-204 (26, 27) 
↓ miR-30a-5p (27) 
↓ miR-30d-5p (27) 
↓ miR-32 (24)  
↓ miR-125b-5p (27) 
↓ miR-193b (19) 
↓ miR-99a-5p (27) 
↓ miR-100-5p (27)  
↓ miR-126-3p (27)  
↓ miR-130a-3p (27) 
↓ miR-10b (24) 
↓ miR-30a-3p (24)  
↓ miR-27b (19) 
Acute T-cell mediated 
rejection (Banff I-II) 
Wilflingseder et al., 2013 
(19) 
T-cell mediated 
rejection (n=30) 
normal PBX (n=10) 
Biopsy ↑ 4 miRs 
↓ 18 miRs 
- ↑ miR-155 (24, 
25, 28) 
↑ miR-150-5p 
(27)  
 
 
↓ miR-125a (25, 27) 
↓ miR-27b (25) 
↓ miR-193b (25) 
↓ miR-181a (26)  
↓ miR-23b-3p (27)  
↓ miR-99b-5p (27) 
Acute rejection Oghumu et al., 2014 (27) AR (heterogeneous) 
(n=5)  
normal T0BX (n=4) 
 
Biopsy ↑ 13 miRs 
↓ 16 miRs 
- ↑ miR-142-3p 
(25, 26, 28)  
↑ miR-223-3p 
(24, 25, 28) 
↑ miR-342-3p 
(25, 26) 
↓ miR-30c-5p (24, 
25) 
↓ miR-125a-5p (19, 
25) 
↓ miR-204-5p (25, 
26) ↓ miR-23b-3p 
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↑ miR-150-5p 
(19) 
 
 
(19) 
↓ miR-30a-5p (25)  
↓ miR-30d-5p (25) 
↓ miR-99b-5p (19) 
↓ miR-99a-5p (25)  
↓ miR-100-5p (25) 
↓ miR-125b-5p (25) 
↓ miR-126-3p (25) 
↓ miR-130a-3p (25) 
Acute rejection Liu et al., 2015 (24) AR (n.o.s) (n=15) 
normal TxBX (n=15) 
 
Biopsy 75 differentially 
expressed miRs 
(fold changes not 
reported) 
 
- ↑ miR-155 (19, 
25, 28) 
↑ miR-223 (25, 
27, 28) 
↑ miR-21 (25) 
↑ miR-125a (23)  
↑ miR-146a (25) 
↑ miR-602 (23) 
↑ miR-628 (23)  
↑ miR-629 (23) 
↑ miR-650 (25) 
↓ miR-30c (25, 27) 
↓ miR-10b (25) 
↓ miR-17-3p (23) 
↓ miR-30a-3p (25) 
↓ miR-32 (25) 
↓ miR-330 (23)  
↓ miR-483 (23) 
↓ miR-611 (23) 
↓ miR-663 (23) 
Acute T-cell mediated 
rejection 
Bijkerk et al., 2017 (29) Discovery cohort:  
stable Tx (clinical) (n=4) 
T-cell mediated 
rejection (n=6) 
 
Validation cohort:  
stable Tx (clinical) 
(n=13)  
T-cell mediated 
rejection (n=13) 
 
Plasma not all 
differentially 
expressed miRs 
reported  
 
 
↑ miR-17 
↑ miR-140-3p 
↑ miR-130b 
↑ miR-122 
↑ miR-192 
 
↓ miR-135a 
↓ miR-199a-3p 
↓ miR-15a 
  
Acute T-cell mediated 
rejection 
Vitalone et al., 2015 (26) T-cell mediated 
rejection (n=29) 
normal TxBX (n=68) 
Biopsy ↑ 3 miRs 
miR-142-3p 
miR-342-3p 
miR-25 
 
↓ 6 miRs 
- ↑ miR-142-3p 
(25, 27, 28) 
↑ miR-342-3p 
(25, 27) 
 
↓ miR-204 (25, 27) 
↓ miR 181a (19)  
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miR-181a 
miR-192 
miR-204 
miR-215 
miR-10b-3p 
miR-615-3p 
Acute T-cell mediated 
rejection (Banff I) 
Soltaninejad et al., 2015 
(28) 
T-cell mediated 
rejection (n=17) 
normal TxBX (n=18) 
Biopsy ↑ 4 miR 
miR-142-5p  
miR-155 
miR-142-3p 
miR-223 
- ↑ miR-155 (19, 
24, 25)  
↑ miR-142-3p 
(25-27)  
↑ miR-223 (24, 
25, 27) 
↑ miR-142-5p 
(25)  
 - 
Acute antibody-
mediated rejection 
Wilflingseder et al., 2013 
(19) 
morphologic antibody-
mediated rejection 
(n=11) 
normal PBX (n=10) 
Biopsy ↑ 6 miRs - - - 
Chronic antibody-
mediated rejection 
 
Danger et al., 2013 (30) chronic antibody-
mediated rejection 
(n=18) 
stable Tx (clinical) 
(n=30) 
AR (heterogeneous) 
(n=9) 
 
 
chronic antibody-
mediated rejection 
(n=21) 
normal TxBx (n=18) 
 
peripheral blood 
mononuclear 
cell 
 
 
 
 
Biopsy 
 
not all 
differentially 
expressed miRs 
reported  
 
↑ miR-142-5p 
↑ miR-142-5p 
 
 
 
 
- 
- 
 
 
 
 
- 
- 
 
 
 
 
- 
Chronic antibody-
mediated rejection 
Rascio et al., 2015 (31) 
 
Discovery cohort:  
chronic ABRM (n=5) 
normal PBX (n=5) 
 
Validation cohort:  
peripheral blood 
mononuclear 
cell 
↓ 16 miRs 
 
  
↓ miR-148b-3p 
↓ miR-769-5p 
↓ miR-29b-3p 
 
 
- - 
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chronic antibody-
mediated rejection 
(n=5) 
normal PBX (n=5) 
Acute pyelonephritis Oghumu et al., 2014 (27) APN (n=11) 
AR (heterogeneous) 
(n=5) 
Biopsy ↑ 24 miRs 
↓ 1 miR 
- - - 
IF/TA Scian et al., 2011 (32) Discovery cohort: 
IF/TA (n=13) 
normal PBX (n=5) 
 
Validation cohort:  
IF/TA (n=19) 
normal PBX (n=8)  
Biopsy 56 differentially 
expressed miRs 
(fold changes not 
reported) 
↑ miR-142-3p 
↑ miR-32 
 
↓ miR-204 
↓ miR-107 
↓ miR-211 
↑ miR-142-3p 
(33, 34) 
↓ miR-211 (34) 
IF/TA Ben-Dov et al., 2012 (33) Discovery cohort: 
n=4 IF/TA  
n=4 normal PBX  
 
Validation cohort:  
n=10 IF/TA 
n=8 normal PBX 
Biopsy ↑ 28 miRs 
↓ 7miRs 
↑ miR-142-3p 
↑ miR-142-5p 
↑ miR-21-5p 
↑ miR-21-3p 
↑ miR-223 
 
↓ miR-30b 
↓miR-30c 
↓ miR-338-3p 
↑ miR-142-3p 
(32, 34)  
↑ miR-21-5p (35) 
↑ miR-142-5p 
(34) 
- 
IF/TA Glowacki et al., 2013 
(35) 
severe graft fibrosis 
(explant) (n=11) 
non-pathologic 
parenchyma of urologic 
cancer (kidney/urinary 
tract) (n=12) 
Biopsy ↑ miR-21 - ↑ miR-21 (33) - 
IF/TA Soltaninejad et al., 2015 
(34) 
IF/TA (n=16) 
normal TxBX (n=17) 
Biopsy ↑ miR-142-3p 
↑ miR-142-5p 
 
↓ miR-211 
- ↑ miR-142-3p 
(32, 33) 
↑ miR-142-5p 
(33) 
 
- 
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Phenotype Study (author) Study population Sample miR Internal 
validation 
Overlap with other studies 
Upregulation Downregulation 
Ischemia/reperfusion 
injury 
Amrouche et al., 2016 
(21) 
LD (n=16) 
DD (n=35) 
Urine pellet ↑ miR-146a 
 
- - - 
Acute T-cell mediated 
rejection 
(Borderline, Banff I-II) 
Lorenzen et al., 2011 
(36) 
Discovery cohort:  
T-cell mediated 
rejection (n=5) 
normal PBX (n=5) 
 
Validation cohort:  
T-cell mediated 
rejection (n=68) 
normal PBX (n=20) 
UTI (n=13) 
Total urine ↑ 5 miRs 
↓ 16 miRs 
 
 
 
↑ miR-10a 
 
↓ miR-210 
↓ miR-10b 
 
- - 
Acute T-cell mediated 
rejection (Banff I-II) 
Betts et al., 2014 (37) T-cell mediated 
rejection (n=8) 
pre-T-cell mediated 
rejection (n=3) 
post-T-cell mediated 
rejection (n=6) 
1 year-T-cell mediated 
rejection (n=6) 
healthy controls (n=4) 
Serum ↑ miR-223 
↑ miR-10a 
- - - 
Acute rejection Tao et al., 2015 (38) Discovery cohort:  
AR (n.o.s) (n= 4) 
stable Tx (clinical) (n= 4) 
 
Validation cohort:  
AR (n.o.s) (n=12) 
delayed graft function 
(n=15) 
stable Tx (clinical) 
(n=11) 
Serum ↑ 6 miRs 
 
 
↑ miR-99a 
↑ miR-100 
- - 
T-cell mediated 
rejection 
Millán et al., 2017 (39) T-cell mediated 
rejection (n=8) 
Urine pellet ↑ miR-155 
↑ miR-142-3p 
- - - 
32 
 
 
 
no T-cell mediated 
rejection (n=71) 
 
↓ miR-210-3p 
Acute T-cell mediated 
vascular rejection (Banff 
II-III) 
Matz et al., 2016 (40) Discovery cohort: 
stable Tx (clinical) (n = 
4) 
T-cell mediated vascular 
rejection (n = 4) 
 
Validation cohort:  
T-cell mediated vascular 
rejection (Banff II-III) 
(n=24) 
stable Tx (clinical) 
(n=40) 
UTI (n=11) 
Borderline (n=17) 
Banff IA-IB (n=15) 
antibody-mediated 
rejection (n=15) 
Mixed T-cell mediated 
rejection-antibody-
mediated rejection 
(n=6) 
IF/TA (n=33) 
Blood cells 29 miRs 
differentially 
expressed miRs 
(fold changes not 
reported) 
 
 
 
↓ miR-15b 
↓ miR-16 
↓ miR-106a 
↓ miR-103a 
↓ miR-107 
↓ miR-15a 
 
- - 
Chronic antibody-
mediated rejection 
Danger et al., 2013 (30) Discovery cohort:  
chronic antibody-
mediated rejection (n= 
9) 
stable Tx (clinical) 
(n=10) 
 
Validation cohort:  
chronic antibody-
mediated rejection 
(n=18) 
stable Tx (clinical) 
(n=30) 
peripheral blood 
mononuclear 
cell 
 
 
not all 
differentially 
expressed miRs 
reported  
 
 
↑ miR-142-5p 
 
- - 
33 
 
 
 
AR (heterogeneous) 
(n=9) 
IF/TA Scian et al., 2011 (32) IF/TA (n=7) 
normal PBX (n=7) 
 
Prospective validation 
cohort: 
n=36 kidney Tx 
recipients (108 samples) 
Urine pellet ↑ miR-142-3p  
 
↓ miR-211  
↓ miR-204  
 
- 
 
↑ miR-142-3p 
(41) 
 
↓ miR-211 (41)  
↓ miR-204 (41) 
IF/TA Maluf et al., 2014 (41) 1st Discovery cohort: 
IF/TA (n= 10) 
normal PBX (n= 12) 
 
 
Validation cohort:  
IF/TA (n=7) 
normal PBX (n=10) 
 
2nd discovery cohort 
 (3 months post Tx with 
IF/TA 24 months) (n=10) 
 (3 months post Tx 
without IF/TA 24 
months) (n=10) 
 
Prospective validation 
cohort:  
n=66 kidney Tx 
recipients 
(132 samples) 
3-6 months 
18-24 months 
 
Urine pellet 1st Discovery 
cohort:  
↑ 10 miRs 
↓ 12 miRs 
 
 
 
 
 
 
2nd discovery 
cohort 
48 miRs 
differentially 
expressed miRs 
(fold changes not 
reported) 
 
 
 
 
 
 
 
 
↑ miR-142-3p  
 
↓ miR-125b 
↓ miR-203 
↓ miR-204  
↓ miR-211  
 
 
 
 
 
 
 
 
 
Prospective 
validation 
cohort 
↑miR-200 
↑miR-140-3p 
 
↓ miR-99a 
↓miR-200b 
↑ miR-142-3p 
(32) 
 
↓ miR-204 (32) 
↓ miR-211 (32) 
 
IF/TA Glowacki et al., 2013 
(35)  
IF/TA grade I (n=12) 
IF/TA grade II (n=7) 
IF/TA grade III (n=10) 
Serum 
 
 
↑ miR-21 - - - 
34 
 
 
 
no IF/TA (n=13)  
IF/TA Zununi et al., 2017 (42) stable Tx (clinical) 
(n=27) 
IF/TA (n=26) 
(grade I: n=16, grade III: 
n=10) 
Plasma ↑ miR-150 
↑ miR 423-3p 
↓ miR-192 (only 
IF/TA grade III) 
↓ miR-200b 
- - - 
Abbreviations: n: number; Scr: serum creatinine; Tx: transplantation;  CKD: chronic kidney disease; SLE: systemic lupus erythematosus; DD: deceased donor; LD: living donor; AR: acute 
rejection; n.o.s.: not otherwise specified; IF/TA: interstitial fibrosis/tubular atrophy; UTI: urinary tract infection; Tx: transplantation; TxBX: transplant biopsy; PBX: protocol biopsy; miR: 
microRNA; qPCR: quantitative polymerase chain reaction. 
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Figure 1. microRNA biogenesis and function 
microRNA coding regions in the human genome are found either intergenic or in the 
introns of annotated genes. microRNA synthesis starts in the nucleus where most of 
the miRs are transcribed by RNA polymerase II into primary miR transcripts (pri-miR) 
of several kilobases that contain local stem-loop structures. The first step of miR 
maturation is cleavage at the stem of the hairpin structure by a microprocessor 
complex consisting of Drosha (an RNase III protein) together with its cofactor 
DiGeorge Syndrome Critical Region 8 (DGCR8) which releases a small hairpin 
structure of 70 nucleotides that is termed a precursor miR (pre-miR). Following 
nuclear processing, pre-miRs are exported to the cytoplasm by exportin 5 (XPO-5) 
where they are cleaved near the terminal loop by another RNase enzyme called 
Dicer thereby releasing a ~22 nucleotide miR duplex. This duplex is loaded onto an 
Argonaute (AGO) protein to generate the RNA-induced silencing complex (RISC). 
One strand (guide strand) remains in the AGO protein as a biologically active miR 
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whereas the other stand (passenger strand, known as miR*) is degraded. The mature miR as part of the effector RISC binds to the 3’ UTR region of the 
mRNA and mediate mRNA degradation, destabilization or translational inhibition.  
Apart from this canonical pathway, there is an alternative ‘mirtron’ pathway, independent from Drosha and DGCR8. Mirtrons are miRs that originate from 
spliced-out introns and that are created when small RNAs bind to the termini of small intronic hairpins (6). Pre-microRNA hairpins with 3’ overhangs are so 
formed and can mature into 22 nucleotides structures, which look and function as normal miRs.  
microRNAs exert their repressive function intracellularly, but are also released into the extracellular compartment, with this initiating their role as 
important intercellular communicators as they are taken up by recipient cells. microRNA can be released passively following cell death or injury, or can be 
actively secreted in different types of extracellular vesicles, including exosomes, microvesicles and apoptotic bodies. Circulating microRNAs form complexes 
with RNA binding proteins including Argonaute 2 proteins and lipoproteins (HDL and LDL), which protects them from RNAse-dependent degradation. 
Abbrevations: RNA pol II: RNA polymerase 2; DGCR8: DiGeorge Syndrome Critical Region 8; XPO-5: exportin-5; miRISC: microRNA-induced silencing 
complex; AB: apoptotic body; MV: microvesicle; E: exosome; Ago: Argonaute protein; LDL: low density lipoprotein; HDL: high density lipoprotein 
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Figure 2. microRNA involved in the NFkB pathway in AKI  
miR-107, miR-101, miR-16 and miR-494 and their targets in the NFκB pathway in the pathophysiology of acute kidney disease.  
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Abbrevations: TNF: tumor necrosis factor; TNFR: TNF receptor; NFκB: nuclear factor κB; IKK: I κB kinase; c-Rel, p50, p52, p65 and RelB : NF-κB transcription 
factor family members ; ATF3: activating transcription factor 3; IL: interleukin; Fas: first apoptosis signal; c-FLIP: cellular FLICE-like inhibitory protein ; BCL-2: 
B-cell lymphoma-2 
 
 
 
 
